Cerulean Closes Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cerulean Pharma (CERU) Announces Publication of Positive CRLX101 Data
April 13, 2015 7:14 AM EDTCerulean Pharma (Nasdaq: CERU) announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Ceruleans lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.
The results of the study demonstrate that CRLX101, a dual topoisomerase-1 and HIF-1 inhibitor, blocks the HIF-1 mediated increase in cancer stem cells induced by Avastin® (bevacizumab) in a triple-negative breast cancer xenograft... More
